Intelligence · Clinical Pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
- Programs
- 5,568
Quick answer
Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 401 programs
- United Therapeutics Europe 219 programs
- George Institute for 174 programs
- Takeda 163 programs
- AstraZeneca 145 programs
- HOFFMANN-LA ROCHE 145 programs
- MSD Merck Sharp 131 programs
- Anaxis Pharma 129 programs
- Regeneron UK 128 programs
- Telethon Foundation 113 programs
- Novartis India 112 programs
-
TRU-016 and bendamustine
Aptevo Therapeutics
Chronic Lymphocytic Leukemia (CLL)
1 trial -
TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets
AstraZeneca AB
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
1 trial -
TS-1 with cisplatin
Hospital Authority, Hong Kong
Recurrent Gastric Cancer
1 trial -
TTI-101
Tvardi Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial -
TTI-101
Tvardi Therapeutics
Hepatocellular Carcinoma
1 trial -
TTX-MC138
Transcode Therapeutics
Advanced Solid Tumor
1 trial -
TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets
Ningbo Cancer Hospital
Non-resectable locally advanced or metastatic HER2-positive breast cancer
1 trial -
TYRA-300
Tyra Biosciences
Locally Advanced Urothelial Carcinoma
1 trial -
Tabelecleucel
Evidence Based Cataract Study Group
Nasopharyngeal Carcinoma
1 trial -
Tagraxofusp
Stemline Therapeutics B.V.
Acute Myeloid Leukemia
1 trial -
Tak-228 & Tak-117
Takeda
Triple Negative Breast Cancer
1 trial -
Talazoparib Tosylate
BioMarin Pharmaceutical Australia Pty Ltd
Advanced Breast Cancer
1 trial -
Tarlatamab
Amgen
Relapsed/Refractory Small Cell Lung Cancer
1 trial -
Tarlatamab, TARLATAMAB, Tarlatamab, SILTUXIMAB
Amgen
Relapsed/Refractory Small Cell Lung Cancer
1 trial -
Tarlatamab, Tarlatamab
The George Institute
Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)
1 trial -
Tarlatamab, Tarlatamab
Partner Therapeutics Limited
Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
1 trial -
Tas-102(Suyuan) combined with bevacizumab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Tasigna 150 mg hard capsules, Scemblix 40 mg film-coated tablets
Fondazione Telethon ETS
BCR-ABL1+ Chronic Myeloid Leukemia
1 trial -
Taxotere
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Tazemetostat
Eisai Co.,
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Tour Hekla
Muscle-invasive bladder cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
The George Institute
Locally advanced cervical cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Wuhan Createrna Science and Technology Co., Ltd
Limited disease small-cell lung cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Disc Medicine
(Diffuse) Large B-cell Lymphoma
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Muscle-invasive bladder cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.
The George Institute
Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent
The George Institute
Adult participants with metastatic (advanced) solid tumors.
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé
CERO THERAPEUTICS HOLDINGS, INC.
microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.
The George Institute
Non resectable Hepatocellular carcinoma (HCC)
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab
Disc Medicine
Squamous cell carcinoma of the anal canal
1 trial -
Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.
Ningbo Cancer Hospital
Hepatocellular carcinoma
1 trial -
Tecentriq 840 mg concentrate for solution for infusion
Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab
Hoffmann-La Roche
Solid tumors
1 trial -
Tegafur Gimeracil Oteracil Potassium Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Telehealth Intervention
United Therapeutics Europe Ltd
Colorectal Cancer
1 trial -
Telisotuzumab Vedotin
AbbVie Deutschland GmbH & Co. KG
Non-Small Cell Lung Cancer
1 trial -
Telisotuzumab adizutecan
AbbVie Deutschland GmbH & Co. KG
Colorectal Cancer
1 trial -
Temsirolimus
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
1 trial -
Teniposide administration
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Tepotinib
Serono Europe Limited
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
1 trial -
Tepotinib
Merck Sharp and Dohme
Lung Cancer
1 trial -
Testosterone Enanthate 100 MG/ML Injectable Solution
Hospital Authority, Hong Kong
Castration-resistant Prostate Cancer
1 trial -
Testosterone cypionate
United Therapeutics Europe Ltd
Castration Resistant Metastatic Prostate Cancer
1 trial -
Teverelix TFA
Nordic Bioscience A/S
Advanced prostate cancer
1 trial -
Tevimbra 100 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.
1 trial -
Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione
Fondazione Telethon ETS
stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Thalidomide and methotrexate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T-LGL Leukemia
1 trial -
The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.
Data attribution: Data sources · All pipeline programs